Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Sell
38
MRSN Quote, Financials, Valuation and Earnings
Last price:
$0.37
Seasonality move
:
-5.16%
Day range:
$0.35 - $0.37
52-week range:
$0.26 - $2.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.31x
P/B ratio:
57.95x
Volume:
2.6M
Avg. volume:
2.8M
1-year change:
-84.87%
Market cap:
$44.9M
Revenue:
$40.5M
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.29, Mersana Therapeutics has an estimated upside of 1090.48% from its current price of $0.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.36.
Fair Value
-
According to the consensus of 9 analysts, Mersana Therapeutics has 1090.48% upside to fair value with a price target of $4.29 per share.
MRSN vs. S&P 500
-
Over the past 5 trading days, Mersana Therapeutics has underperformed the S&P 500 by -7.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mersana Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mersana Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Mersana Therapeutics reported revenues of $2.8M.
Earnings Growth
-
Mersana Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mersana Therapeutics reported earnings per share of -$0.19.
Enterprise value:
-37M
EV / Invested capital:
3.54x
Price / LTM sales:
1.31x
EV / EBIT:
--
EV / Revenue:
-1.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-46.02%
Net Income Margin (TTM):
-217.64%
Return On Equity:
-533.43%
Return On Invested Capital:
-316.06%
Operating Margin:
-890.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $32.3M | $38.3M | $34M | $9.2M | $2.8M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$215M | -$134.2M | -$76.8M | -$21M | -$24.5M | |
| EBITDA | -$208.5M | -$129.1M | -$68.4M | -$17.9M | -$23M | |
| Diluted EPS | -$2.12 | -$1.14 | -$0.59 | -$0.16 | -$0.19 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $232M | $241.5M | $281.8M | $187.5M | $106.2M | |
| Total Assets | $247.9M | $258.3M | $296.2M | $198.4M | $112.5M | |
| Current Liabilities | $34.9M | $56.5M | $83.4M | $53.4M | $58.2M | |
| Total Liabilities | $50M | $117.7M | $231.9M | $170.4M | $143.3M | |
| Total Equity | $197.9M | $140.5M | $64.3M | $28M | -$30.9M | |
| Total Debt | $5M | $24.7M | $25M | $25.3M | $20.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.4M | -$172.5M | -$79M | -$32.7M | -$29.3M | |
| Cash From Investing | -$151M | $45.9M | $111M | -$72.5M | $27M | |
| Cash From Financing | $114.2M | $79M | -$4.9M | $5.8M | -$3.1M | |
| Free Cash Flow | -$73.2M | -$173.9M | -$79M | -$32.8M | -$29.3M | |
MRSN
Sector
Market Cap
$44.9M
$34.7M
Price % of 52-Week High
12.72%
42.33%
Dividend Yield
0%
0%
Shareholder Yield
2.41%
-0.66%
1-Year Price Total Return
-84.87%
-41.18%
Beta (5-Year)
1.319
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.36
200-day SMA
Sell
Level
$1.23
Bollinger Bands (100)
Sell
Level
0.26 - 0.82
Chaikin Money Flow
Buy
Level
28.4M
20-day SMA
Sell
Level
$0.36
Relative Strength Index (RSI14)
Sell
Level
49.26
ADX Line
Buy
Level
14.68
Williams %R
Neutral
Level
-52.8926
50-day SMA
Sell
Level
$0.37
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-126.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.6062)
Sell
CA Score
(Annual)
Level (-3.9147)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.6134)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company’s next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Stock Forecast FAQ
In the current month, MRSN has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MRSN average analyst price target in the past 3 months is $4.29.
-
Where Will Mersana Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mersana Therapeutics share price will rise to $4.29 per share over the next 12 months.
-
What Do Analysts Say About Mersana Therapeutics?
Analysts are divided on their view about Mersana Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mersana Therapeutics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Mersana Therapeutics's Price Target?
The price target for Mersana Therapeutics over the next 1-year time period is forecast to be $4.29 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MRSN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mersana Therapeutics is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRSN?
You can purchase shares of Mersana Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mersana Therapeutics shares.
-
What Is The Mersana Therapeutics Share Price Today?
Mersana Therapeutics was last trading at $0.37 per share. This represents the most recent stock quote for Mersana Therapeutics. Yesterday, Mersana Therapeutics closed at $0.36 per share.
-
How To Buy Mersana Therapeutics Stock Online?
In order to purchase Mersana Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 28
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
